Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2181-2200 of 3,900 trials

Relapsing Multiple Sclerosis: YTB323 Treatment Study

We are testing a new treatment called YTB323 for people with Relapsing Multiple Sclerosis who have had ongoing disease activity despite previous therapies. The study aims to assess its safety and effects on disease progression.

Relapsing Multiple Sclerosis1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesNeurology

INZ-701 for ENPP1 and ABCC6 Deficiency

We are studying the long-term safety of INZ-701 in patients with ENPP1 and ABCC6 deficiencies. This trial will help us understand how the drug works over time and its effects on certain blood markers.

Pseudoxanthoma ElasticumEctonucleotide Pyrophosphatase/Phosphodiesterase 1 DeficiencyGeneralized Arterial Calcification of InfancyEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal Medicine

BP1.7881: Safety Study in Healthy Volunteers

We are testing a new medication to see how safe it is and how the body handles it. This study will also look at its effects on heart function in healthy individuals.

Eosinophilic EsophagitisSafety phase (I)AllergologyGastroenterology

Colon Cancer: HIPEC with Mitomycin-C Study

We are investigating whether adding a special chemotherapy during surgery helps prevent cancer recurrence in patients with colon cancer that has spread to the abdomen. This study compares outcomes for those receiving this treatment versus standard care.

Peritoneal Metastases of Colorectal Cancer>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesOncology

Pain Relief for First-Degree Perineal Tears: Emla Cream vs. Injection

We are comparing a topical cream to an injection for pain relief in women with first-degree perineal tears after childbirth. The goal is to see which method provides better comfort during and after the repair.

First-Degree Perineal Laceration6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics

Pemigatinib for Solid Tumors with FGFR Alterations

We are studying whether pemigatinib can help patients with recurrent or metastatic solid tumors that have a specific gene change. The trial aims to assess its effects on tumor growth and overall patient health.

Recurrent or Metastatic Solid Cancer with FGFR Alterations>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Multiple Myeloma: Venetoclax and Dexamethasone Study

We are investigating whether a combination of venetoclax and dexamethasone is effective for patients with relapsed and refractory multiple myeloma who have the translocation (11;14). This study aims to find out if this treatment can improve outcomes for these patients.

Multiple Myeloma>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesHematologyOncology

Acute Myeloid Leukemia: Revumenib with Azacitidine and Venetoclax

We are studying whether adding revumenib to azacitidine and venetoclax helps adults with newly diagnosed NPM1-mutated AML who cannot receive intensive chemotherapy. The goal is to see if this combination improves survival and treatment response.

Acute Myeloid LeukemiaConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOncology

Pancreatic Cancer: CEB-01 Treatment Study

We are exploring a new treatment called CEB-01 for people with pancreatic cancer to see how safe it is and if it may help improve their condition.

Pancreatic Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Migraine Treatment in Kids: Rimegepant Study

We are studying the effectiveness of rimegepant for treating migraines in children and adolescents aged 6 to under 18. The goal is to see if it helps relieve pain and other symptoms better than a placebo.

Migraine3-6 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesPartially RemoteNeurologyPediatrics

Migraine Treatment: Rimegepant for Kids and Teens

We are studying the safety of rimegepant for treating migraines in children and adolescents aged 6 to under 18. This trial will help us understand how well the medication works and if there are any side effects.

Migraine1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Non-Transfusion-Dependent Thalassemia: Mitapivat Study

We are studying whether Mitapivat can improve anemia in people with non-transfusion-dependent alpha or beta thalassemia. This trial compares the medication to a placebo to evaluate its effects.

Non-Transfusion Dependent Thalassemia3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematology

Acute Myeloid Leukemia: Ivosidenib, Azacitidine, and Venetoclax Study

We are investigating whether adding venetoclax to ivosidenib and azacitidine helps patients with newly diagnosed IDH1-mutated AML who cannot undergo intensive chemotherapy. The goal is to see if this combination improves survival and remission rates.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOncology

Septic Shock: Landiolol Infusion Study

We are investigating whether Landiolol can improve blood flow and heart function in patients with septic shock. This study compares its effects to standard treatments for managing rapid heart rates.

Microcirculatory Abnormalities in Septic Shock>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Tuberculosis Treatment: Tedizolid vs. Linezolide

We are studying how well tedizolid works compared to linezolide in reducing tuberculosis bacteria in patients. This trial aims to find out which treatment may be more effective in the first days of therapy.

Multidrug-Resistant TuberculosisEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Advanced Solid Tumors: VERT-002 Study

We are studying a new anticancer drug, VERT-002, for patients with advanced solid tumors, including lung cancer with MET alterations. The trial aims to assess its safety and how well it may work.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Remyelination in Multiple Sclerosis: PET-MR Study

We are investigating how myelin repair happens in people with multiple sclerosis using advanced imaging techniques. This study aims to understand the role of neuroinflammation in the repair process.

Progressive Relapsing Multiple Sclerosis>2 yearsConfirmation phase (III)Neurology

Vitiligo Treatment: Methotrexate and UVB Phototherapy

We are studying whether combining methotrexate with UVB phototherapy helps adults with progressive vitiligo achieve better skin repigmentation. We will also assess the safety of this treatment and its impact on quality of life.

Vitiligo>2 yearsEfficacy phase (II)Investigational MedicinesDermatology

Facial Lines: IPN10200 Treatment Study

We are studying a new treatment for adults with moderate to severe upper facial lines to see if it improves their appearance compared to a placebo. The trial will assess both safety and effectiveness of the treatment.

Frown Lines6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesDermatology

HIV Control: Pomalidomide Study

We are studying whether pomalidomide can help control HIV in people on treatment who take a break from their medication. The trial also examines its effects on the immune system and HIV persistence.

HIV-1 Infection3-6 monthsSafety phase (I)Efficacy phase (II)11-15 visitsStandard MedicinesInfectious DiseasesInternal Medicine